Pacira Biosciences, Inc. · NASDAQ:PCRX

Pacira Biosciences — Merger or Acquisition (October 2021)

12 slides from Pacira Biosciences's merger presentation, Oct 12, 2021

  1. Slide 1: Pacira to Acquire Flexion, Further Expanding Leadership Position in Non-Opioid Pain Management

    Pacira to Acquire Flexion, Further Expanding Leadership Position in Non-Opioid Pain Management October 11, 2021

  2. Slide 2: Forward-looking statements and where to find additional information

    Forward-looking statements and where to find additional information 2 Any statements in this communication about Pacira BioSciences, Inc.’s (“Pacira”) or Flexion Therapeutics, Inc.’s (“Flexion”) future expectations, plans, trends, outlook, projections and prospects, and other statements containing t

  3. Slide 3: Agenda

    Agenda 3 1 Overview and Opportunity Strategic Rationale Financial Overview and Transaction Details Q&A Dave Stack Chief Executive Officer and Chairman Ron Ellis, DO, MBA Senior Vice President Corporate Strategy & Business Development Charles A. Reinhart III Chief Financial Officer Dave Stack Ron Ell

  4. Slide 4: Pacira growth pillars in non-opioid pain management further bolstered by Flexion

    Pacira growth pillars in innovative non-opioid pain management and regenerative health solutions further bolstered by Flexion 4 PursuingInnovation 2 1 ExpandingProductUtilization TWO GLOBAL GROWTH PILLARS FURTHER ENHANCED Core Values Patient-centered, determined, passionate, innovative thinkers, tru

  5. Slide 5: Osteoarthritis affects 30+ million Americans and costs >$185 billion in annual expenses

    1. Wright EA, Katz JN, Abrams S, Solomon DH, Losina E. Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritis. Arthritis Care Res (Hoboken). 2014;66(10):1489-95. 2. Williams AR, Bisaga A. From AIDS to opioids – how to combatan epidemic. N Engl J Med 2016;375(9):813-815

  6. Slide 6: Building a differentiated portfolio of opioid-sparing solutions along the neural pain pathway

    Building a differentiated portfolio of opioid-sparing solutions along the neural pain pathway 6 Pre-surgical pain (’Prehabilitation’) Strategic focus: Building non-opioid and regenerative medicine franchises across the continuum of care Pain; Injury/trauma (Regenerative medicine) Osteoarthritis pain

  7. Slide 7: Commercial potential for ZILRETTA in OA of the knee

    Commercial potential for ZILRETTA in OA of the knee3 ZILRETTA overview and addressable opportunity 7 Patients treated for knee OA in 2018: ~15.2M Treated with intra-articular (IA) injection2: ~5M Patients with steroid injections: ~4.5M X Average number of treatments per patient/year: ~1.5 Patients w

  8. Slide 8: Transaction rationale

    Transaction rationale 8 Portfolio Expanding pain continuum Immediate synergies Robust milestones Financial impact • Innovative non-opioid portfolio highly complementary to EXPAREL and iovera⁰; directly aligns with the Pacira mission and strategy to address medical needs along the neural pain pathway

  9. Slide 9: Transaction terms and financing

    • Under the terms of the definitive agreement, Pacira to commence a tender offer to acquire all outstanding shares of Flexion for a purchase price of $8.50 per share in cash plus one non-tradeable CVR • The CVR entitles Flexion stockholders and certain holders of Flexion stock options to up to an ad

  10. Slide 10: Pacira third quarter performance

    • EXPAREL net product sales of $121.9 million for the third quarter and $39.7 million for the month of September 2021, compared with $113.7 million and $39.5 million in the prior year, respectively – The elective surgery market faced additional pandemic-related challenges in August and September due

  11. Slide 11: Transaction makes Pacira earnings outlook even more compelling

    Transaction makes Pacira earnings outlook even more compelling 11 1 Creates diversification and growth to topline Meaningful synergies to drive substantial near- and long-term accretion Expands leadership position in non-opioid pain management • Differentiated commercial portfolio of end-to-end non-

  12. Slide 12: Questions?

    Questions? PACIRA

Pacira BioSciences — Merger or Acquisition (October 2021) on 6ix